LENZ Therapeutics, Inc.
LENZ
Positions held
Your positionsLENZ isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $110.91M | Enterprise value | -$108.52M | Trailing P/E | — | Forward P/E | -1.15 |
| PEG | — | Price / book | 0.51 | Beta | 1.73 | Dividend yield | 0.00% |
| Revenue growth | 9.7% | Earnings growth | — | Gross margin | 91.7% | Operating margin | -6.2% |
| Profit margin | 0.0% | ROE | -59.2% | ROA | -37.4% | Debt / equity | 0.00 |
| Current ratio | 13.55 | Free cash flow | -$71.25M | Analyst recommendation | none | Mean target | $24.00 |
| 52w high | $49.16 | 52w low | $3.35 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $5.5M | $1.9M | $1.6M | $12.5M | $5.0M | — |
| Op margin | -622.9% | -2321.7% | -2422.1% | -151.1% | -337.1% | — |
| Net income | -$31.9M | -$41.5M | -$35.9M | -$16.7M | -$14.9M | — |
| Gross margin | 94.9% | 43.4% | — | — | 100.0% | — |
| Gross profit | $5.2M | $0.8M | — | — | $5.0M | $0.0M |
| Operating income | -$34.2M | -$44.1M | -$38.5M | -$18.9M | -$16.9M | — |
- Revenue +189% vs prior quarter ($5.5M vs $1.9M).
- Gross margin 94.9% (was 43.4% prior quarter).
- Operating margin expanded to -622.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $19.1M | $0.0M | $0.0M | $15.0M |
| Op margin | -477.5% | — | — | -69.9% |
| Net income | -$82.1M | -$49.8M | -$70.0M | -$10.8M |
| Gross margin | 97.8% | — | — | — |
| Gross profit | $18.7M | $0.0M | — | — |
| Operating income | -$91.1M | -$58.6M | -$72.4M | -$10.5M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-08-19 · LENZ Therapeutics (LENZ) Q2 2026 Earnings Call Transcript
2026-08-15 · LENZ Therapeutics (LENZ) Stock Sees Fair Value Moves Lower After Analyst Target Cuts
2026-08-12 · LENZ Therapeutics Inc (LENZ) (Q2 2026) Earnings Call Highlights: VIZZ Launch Momentum ...
2026-08-12 · LENZ Therapeutics, Inc. Q2 2026 Earnings Call Summary
2026-08-11 · LENZ Therapeutics Q2 Earnings Call Highlights
2026-08-11 · LENZ Therapeutics, Inc. (LENZ) Reports Q2 Loss, Beats Revenue Estimates
2026-08-11 · LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-08-10 · LENZ Therapeutics Inc (LENZ) Q2 2026 Earnings Report Preview: What To Look For
2026-08-06 · CG Oncology, Inc. (CGON) Reports Q2 Loss, Misses Revenue Estimates
2026-08-04 · LENZ Therapeutics to Report Second Quarter 2026 Financial Results and Recent Corporate Highlights on August 11, 2026
2026-07-23 · Alnylam Pharmaceuticals (ALNY) Reports Next Week: Wall Street Expects Earnings Growth
2026-07-22 · Earnings Preview: LENZ Therapeutics, Inc. (LENZ) Q2 Earnings Expected to Decline
Price (daily)
Full chart · RSI · MACD · patterns